Lipoprotein associated phospholipase A2 enzyme; possible new roles and inhibition for therapeutic intervention

Manoj G. Tyagi, Sumith K. Mathew


Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) is a 45-kDa protein of 441 amino acids encoded by the pla2g7 gene in the humans. In the blood it is associated mainly with Low Density Lipoprotein (LDL) and less than 20% is associated with High Density Lipoprotein (HDL). This enzyme is characterized by its ability to specifically hydrolyze PAF as well as glycerophospholipids containing short, truncated, and/or oxidized fatty acyl groups at the sn-2 position of the glycerol backbone. Genetic studies conducted in humans harboring an inactivating mutation at this locus suggest that loss of Lp-PLA2 function is a risk factor for inflammatory and vascular conditions. Consistently, overexpression of Lp-PLA2 has anti-inflammatory or pro-inflammatory actions and anti-atherogenic properties in animal models. This article discusses two simple techniques to estimate Lp-PLA2 activity. New therapeutic agents inhibiting the activity of Lp-PLA2 are being investigated for curative purpose.


PLA2, Phospholipid, Inflammation, Thyroxine, Grave’s disease, PAF

Full Text:



Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006;1761:1246-59.

Farr RS, Cox CP, Wardlow ML, Jorgensen R. Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin Immunol Immunopathol. 1980;15:318-30.

Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419-45.

Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor. J Biol Chem. 1990;265:17381-4.

Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem. 1990;265:9682-7.

Rosenson RS. Lp-PLA2 and risk of atherosclerotic vascular disease. Lancet. 2010;375:1498-500.

Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem. 1995;270:31151-7.

Steingrimur Stefansson, R. Manjunatha Kini, Herbert J. Evans. The basic phospholipase A2 from Naja nigricollis venom inhibits the prothrombinase complex by a novel nonenzymic mechanism. Biochem. 1990;29(33):7742-6.

Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3(2):57-68.

Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215-22.

Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007;104:15490-5.

Martinez-Triguero ML, Hernandez-Mijares A, Nguyen TT, Munoz ML, Pena H, Morillas C, Lorente D, Lluch I, Molina E. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc. 1998;73:837-41.

Hok-Hay S. Oei, Irene M. van der Meer, Albert Hofman, Peter J. Koudstaal, Theo Stijnen, Monique MB. Breteler, Jacqueline CM. Witteman. Lipoprotein-associated phospholipase A2. Circulat. 2005;111:570-5.

Tetsuya Kosaka, Masahiro Yamaguchi, Yasuji Soda, Tatsuya Kishimoto, Akio Tago, Mitsuyoshi Toyosato, Koji Mizuno. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta. 2000 Jun;296(1-2):151-61.

Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atheroscler. 2000 Jun;150(2):413-9.

Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23(5):829-35.

De Keyzer D, Karabina SA, Wei W, Geeraert B, Stengel D, Marsillach J, Camps J, Holvoet P, Ninio E. Increased PAF-AH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2009;29:2041-6.

Suckling KE, Macphee CH. Lipoprotein-associated phospholipase A2: a target directed at that atherosclerotic plaque. Expert Opin Ther Targets. 2002 Jun;6(3):309-14.

Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab. 1998;83:1752-5.

Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:267-93.

Sundaram V, Hanna AN, Koneru L, Newman HA, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab. 1997;82:3421-4.

Bech K, Damsbo P, Eldrup E, Beck-Nielsen H, Roder ME, Hartling SG, Volund A, Madsbad S. Beta-cell function and glucose and lipid oxidation in Graves’ disease. Clin Endocrinol. 1996;44:59-66.

Santi A, Duarte MM, Moresco RN, Menezes C, Bagatini MD, Schetinger MR, Loro VL. Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clin Chem Lab Med. 2010;48(11):1635-9.

Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke. 2005 Jul;36(7):1372-6.

Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atheroscler. 2010;208(1):10-8.

Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 1989;30(3):305-15.

Müller J, Petković M, Schiller J, Arnold K, Reichl S, Arnhold J. Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Luminescence. 2002;17(3):141-9.

O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulat. 2006;113(14):1745-52.

Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95(9):1025-32.

Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A. Darapladib investigators: the effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51(17):1632-41.